Licochalcone A inhibits the formation and bone resorptive activity of osteoclasts

Cell Biology International

Volumn 32, Issue 9, 2008, Pages 1064-1072

  Kim, Soon Nam ^a,b   Kim, Myung Hee ^a,b   Min, Yong Ki ^a   Kim, Seong Hwan ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

Bone resorption; ERK; Fra 2; Licochalcone A; NF B; Osteoclast formation

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LICOCHALCONE A; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR FRA 2;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS;

ANIMALS; BONE RESORPTION; CELL SURVIVAL; CELLS, CULTURED; CHALCONES; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; I-KAPPA B PROTEINS; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASES; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; RANK LIGAND; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR RELA;

EID: 49749135501     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2008.04.017     Document Type: Article

References (41)

1. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., et al. Auto amplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202 (2005) 1261-1269
2. Bharti A.C., Takada Y., and Aggarwal B.B. Curcumin (diferuloylmethane) inhibits receptor activator of NF-κB ligand-induced NF-κB activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 172 (2004) 5940-5947
3. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
4. Chen M., Christensen S.B., Blom J., Lemmich E., Nadelmann L., Fich K., et al. Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania. Antimicrob Agents Chemother 37 (1993) 2550-2556
5. Eferl R., Hoebertz A., Schilling A.F., Rath M., Karreth F., Kenner L., et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J 23 (2004) 2789-2799
6. Fu B., Li H., Wang X., Lee F.S., and Cui S. Isolation and identification of flavonoids in licorice and a study of their inhibitory effects on tyrosinase. J Agric Food Chem 53 (2005) 7408-7414
7. Fu Y., Hsieh T.C., Guo J., Kunicki J., Lee M.Y., Darzynkiewicz Z., et al. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem Biophys Res Commun 322 (2004) 263-270
8. Halleen J.M., Raisanen S.R., Alatalo S.L., and Vaananen H.K. Potential function for the ROS-generating activity of TRACP. J Bone Miner Res 18 (2003) 1908-1911
9. Halleen J.M., Raisanen S., Salo J.J., Reddy S.V., Roodman G.D., Hentunen T.A., et al. Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 274 (1999) 22907-22910
10. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96 (1999) 3540-3545
11. Hwang Y.H., Lee J.W., Hahm E.R., Jung K.C., Lee J.H., Park C.H., et al. Momordin I, an inhibitor of AP-1, suppressed osteoclastogenesis through inhibition of NF-κB and AP-1 and also reduced osteoclast activity and survival. Biochem Biophys Res Commun 337 (2005) 815-823
12. Ishibashi O., Niwa S., Kadoyama K., and Inui T. MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. Life Sci 79 (2006) 1657-1660
13. Ishikawa T., Kamiyama M., Tani-Ishii N., Suzuki H., Ichikawa Y., Hamaguchi Y., et al. Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides. Mol Carcinog 32 (2001) 84-91
14. Johnson R.S., Spiegelman B.M., and Papaioannou V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71 (1992) 577-586
15. Kanno S., Hirano S., and Kayama F. Effects of the phytoestrogen coumestrol on RANK-ligand-induced differentiation of osteoclasts. Toxicology 203 (2004) 211-220
16. Kim H.H., Kim J.H., Kwak H.B., Huang H., Han S.H., Ha H., et al. Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge. Biochem Pharmacol 67 (2004) 1647-1656
17. Kolbe L., Immeyer J., Batzer J., Wensorra U., Dieck K.T., Mundt C., et al. Anti-inflammatory efficacy of Licochalcone A: correlation of clinical potency and in vitro effects. Arch Dermatol Res 298 (2006) 23-30
18. Lee Z.H., and Kim H.H. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 305 (2003) 211-214
19. Lee S.E., Woo K.M., Kim S.Y., Kim H.M., Kwack K., Lee Z.H., et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30 (2002) 71-77
20. Lee S.H., Rho J., Jeong D., Sul J.Y., Kim T., Kim N., et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 12 (2006) 1403-1409
21. -ΔΔCT method. Methods 25 (2001) 402-408
22. Lowe C., Yoneda T., Boyce B.F., Chen H., Mundy G.R., and Soriano P. Osteopetrosis in src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 90 (1993) 4485-4489
23. Matsuo K., Owens J.M., Tonko M., Elliott C., Chambers T.J., and Wagner E.F. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24 (2000) 184-187
24. Mi-Ichi F., Miyadera H., Kobayashi T., Takamiya S., Waki S., Iwata S., et al. Parasite mitochondria as a target of chemotherapy: inhibitory effect of licochalcone A on the Plasmodium falciparum respiratory chain. Ann NY Acad Sci 1056 (2005) 46-54
25. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., et al. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 148 (2000) 333-342
26. Morabito N., Crisafulli A., Vergara C., Gaudio A., Lasco A., Frisina N., et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 17 (2002) 1904-1912
27. Okada Y., Naka K., Kawamura K., Matsumoto T., Nakanishi I., Fujimoto N., et al. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase=gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest 72 (1995) 311-322
28. Parfitt A.M. Bone remodeling and bone loss: understanding the pathophysiology of osteoporosis. Clin Obstet Gynecol 30 (1987) 789-811
29. Putnam S.E., Scutt A.M., Bicknell K., Priestley C.M., and Williamson E.M. Natural products as alternative treatments for metabolic bone disorders and for maintenance of bone health. Phytother Res 21 (2007) 99-112
30. Rafi M.M., Rosen R.T., Vassil A., Ho C.T., Zhang H., Ghai G., et al. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res 20 (2000) 2653-2658
31. Rassi C.M., Lieberherr M., Chaumaz G., Pointillart A., and Cournot G. Down-regulation of osteoclast differentiation by daidzein via caspase 3. J Bone Miner Res 17 (2002) 630-638
32. Rozen S., and Skaletsky H.J. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132 (2000) 365-386
33. Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi 120 (2000) 849-862
34. Shibata S., Inoue H., Iwata S., Ma R.D., Yu L.J., Ueyama H., et al. Inhibitory effects of licochalcone A isolated from Glycyrrhiza inflata root on inflammatory ear edema and tumour promotion in mice. Planta Med 57 (1991) 221-224
35. Soriano P., Montgomery C., Geske R., and Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64 (1991) 693-702
36. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3 (2002) 889-901
37. Teitelbaum S.L. Bone resorption by osteoclasts. Science 289 (2000) 1504-1508
38. Tsukiyama R., Katsura H., Tokuriki N., and Kobayashi M. Antibacterial activity of licochalcone A against spore-forming bacteria. Antimicrob Agents Chemother 46 (2002) 1226-1230
39. Wagner E.F., and Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 208 (2005) 126-140
40. Wang Z.Q., Ovitt C., Grigoriadis A.E., Mohle-Steinlein U., Ruther U., and Wagner E.F. Bone and haematopoietic defects in mice lacking c-fos. Nature 360 (1992) 741-745
41. Yamagishi T., Otsuka E., and Hagiwara H. Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. Endocrinology 142 (2001) 3632-3637